Antagonist-induced reversal of functional and structural measures of hippocampal benzodiazepine tolerance

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Chronic administration of benzodiazepines, such as flurazepam (FZP), can lead to the development of tolerance.
• Tolerance to benzodiazepines involves alterations in gamma-aminobutyric acid type A (GABA(A))-receptor subunit expression and function.
• Understanding the mechanisms underlying benzodiazepine tolerance is crucial for managing treatment efficacy and withdrawal symptoms.

Purpose of the Study:

• To investigate the effects of flurazepam (FZP) on anticonvulsant tolerance, GABA(A)-receptor subunit protein expression, and receptor function in rats.
• To determine the efficacy of flumazenil (FLM), a benzodiazepine antagonist, in reversing FZP-induced tolerance and associated molecular changes.
• To explore the interdependent roles of functional and structural adaptations in mediating benzodiazepine tolerance.

Main Methods:

• Rats were administered oral flurazepam (FZP) for one week, followed by single injections of flumazenil (FLM) at varying doses.
• In vivo anticonvulsant tolerance was assessed using the pentylenetetrazole seizure threshold test and the efficacy of zolpidem, an alpha(1)-subunit-selective agonist.
• In vitro electrophysiological recordings in hippocampal slices measured miniature inhibitory postsynaptic current (mIPSC) decay and amplitude.
• [3H]Zolpidem binding assays and quantitative immunohistochemistry were used to evaluate GABA(A)-receptor subunit protein expression (alpha(1) and beta(3)).

Main Results:

• FZP administration induced significant in vivo and in vitro anticonvulsant tolerance, which was partially or fully reversed by FLM.
• FLM pretreatment restored normal mIPSC decay and amplitude in hippocampal slices.
• FZP treatment led to decreased [3H]zolpidem binding, down-regulation of alpha(1)-subunit protein in CA1, and up-regulation of beta subunit protein in CA3, all of which were reversed by FLM.
• FZP-induced changes in alpha(1)- and beta(3)-subunit protein levels were reversed by prior FLM injection.

Conclusions:

• Flumazenil (FLM) effectively reverses both functional and structural adaptations associated with flurazepam (FZP)-induced benzodiazepine tolerance.
• The findings suggest an interdependent relationship between GABA(A)-receptor subunit expression changes and functional tolerance.
• These results provide insights into the neurobiological mechanisms of benzodiazepine tolerance and potential therapeutic strategies for its management.